Croissy-Beaubourg, October 31, 2018, 6:00pm CET – THERADIAG (ISIN: FR0004197747; Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, announces the appointment of Pierre Morgon as Chairman of the Board of Directors of Theradiag following today’s Board meeting.
Pierre Morgon replaces Gérard Tobelem, Chairman of the Board of Directors of Theradiag since 2012, who resigned as Chairman and Director of Theradiag.
Pierre Morgon comments: “On behalf of all Board members, I would like to thank Gérard Tobelem for his role in Theradiag’s development for more than six years. In my new position as Chairman, I will do all I can to support Theradiag’s strategic expansion, particularly in monitoring biotherapies with proven and growing potential.”
Gérard Tobelem adds: “I have full confidence in Pierre as my successor as Chairman of the Board of Directors of Theradiag. I am proud of everything Theradiag has achieved over the years and would like to thank Michel Finance and his teams. I firmly believe that the routine patient monitoring market is entering maturity, driven by the considerable growth of biotherapies in chronic diseases and increasingly precise and personalized medicine.”
Pierre Morgon is a member of Theradiag’s Board of Directors since 2012.
Pierre A. MORGON, 55, is CEO of MRGN Advisors and Regional Partner for Switzerland at Mérieux Equity Partners.
He is Chairman of the Board of Virometix, as well as Non-Executive Director to the Boards of Theradiag, of Eurocine Vaccines, of Vaccitech and of Univercells.
Pierre has over 30 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies.
He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD and IMD.
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases and cancer. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. The Company is based in Marne-la-Vallée, near Paris, and has over 65 employees.
For more information about Theradiag, please visit our website: www.theradiag.com
Tel.: +33 (0)1 64 62 10 12
& Investor Relations
Tel.: +33 (0)1 44 71 94 94
Tel.: +33 (0)1 44 54 36 64